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Abstract
Objective—To present an overview of a series of studies in which the clinical validity of the 
National Institutes of Health’s Patient Reported Outcome Measurement Information System (NIH; 
PROMIS) measures was evaluated, by domain, across six clinical populations.
Study Design and Setting—Approximately 1,500 individuals at baseline and 1,300 at follow-
up completed PROMIS measures. The analyses reported in this issue were conducted post hoc, 
pooling data across six previous studies, and accommodating the different designs of the six, 
within-condition, parent studies. Changes in T-scores, standardized response means, and effect 
sizes were calculated in each study. When a parent study design allowed, known groups validity 
was calculated using a linear mixed model.
Results—The results provide substantial support for the clinical validity of nine PROMIS 
measures in a range of chronic conditions.
Conclusion—The cross-condition focus of the analyses provided a unique and multifaceted 
perspective on how PROMIS measures function in “real-world” clinical settings and provides 
external anchors that can support comparative effectiveness research. The current body of clinical 
validity evidence for the nine PROMIS measures indicates the success of NIH PROMIS in 
developing measures that are effective across a range of chronic conditions.
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1. Introduction
In a succinct seven words, Lee Sechrest summed up the formidable challenge that faces 
researchers who use and develop psychometric instruments: “Validity of measures is no 
simple matter.” [1] Although researchers often describe a scale as “valid” or having been 
“validated,” validity is contextual. It resides, not in the instrument itself, but in the use of the 
scores. A simple example clarifies the relationship between validity and appropriate use 
based on context. Consider a measure of depressive symptoms whose scores are found to 
successfully predict clinical depression. Such a finding supports the validity of using the 
measure’s scores to screen individuals for depression; using scores of this measure to predict 
substance abuse, however, is unlikely to be as successful. Poor predictability of the scores in 
the latter case does not “invalidate” the measure any more than success in the former confers 
global validity to the measure.
In health measurement, among the challenges that make validity “no simple matter” is the 
application of measures in diverse populations and for a range of purposes. Scores are used 
to follow people over time, evaluate interventions, compare the effectiveness of treatments, 
and quantify the impact of disease on quality of life. To evaluate how effective measures are 
for these purposes, it is critical to administer them in clinical contexts and evaluate their 
performance. This is not to say that other considerations are irrelevant. The quality of an 
instrument is influenced by the soundness of the methods used to develop it, and evaluation 
of these methods is a critical component in assessment of a measure’s validity. But the level 
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of validity evidence generated in the typical measurement development study often is 
rudimentary and inadequate for establishing the validity of using scores in clinical contexts 
[2].
For patient-reported outcome (PRO) measures, there are a number of particularly relevant 
validity evaluations. It is important to know how well scores on measures perform in 
quantifying the impact of disease and health problems on domains important to patients, in 
comparing effectiveness of treatments and management strategies, and in tracking the 
longitudinal course of disease. Subjecting well-constructed PRO tools to these critical tests 
of clinical validity is an essential step in the maturation of a new measure.
Well-constructed, generalizable, and clinically relevant PRO measures can be very useful 
when conducting comparative effectiveness research (CER). CER is defined as research 
“designed to inform health care decisions by providing evidence on the effectiveness, 
benefits, and harms of different treatment options” [3]. PRO scores increasingly serve as end 
points in treatment efficacy and effectiveness studies. They can be used to define responding 
(or progressing) patients in clinical trials. Magnitude of change in the PRO score of an 
individual that is required to classify as improved or worsened is specified a priori. 
Treatments are then compared with regard to differences in proportions of responders, 
progressors, or both. Responder analysis is appealing because it embeds meaningful change 
into the consideration of statistical significance. To conduct a responder analysis, however, 
one must answer the difficult question, “How should response to treatment be 
operationalized?” Statistical approaches have been critiqued because of the absence of an 
external anchor and the lack of consensus and empirical support [4]. A more patient-
centered approach is to estimate meaningful change by anchoring to responses to a one-item 
global rating of change (GROC). However, the GROC has been criticized at several levels 
because of its vulnerability to response bias [5]. Clinical validity studies that evaluate 
changes in scores across different conditions and contexts could provide more defensible 
anchors for responder analysis, supporting the science of CER.
This article presents an overview of the five-article series published in this issue. [An 
additional article in this issue is devoted to examining the ecological validity of various 
Patient Reported Outcome Measurement Information System (PROMIS) measures across 
five different populations]. These publications document progress in building a body of 
clinical validity evidence for nine measures from the National Institutes of Health’s (NIH) 
PROMIS [6–12]. Collectively, the findings substantially increase knowledge of the 
appropriate and meaningful applications of these PROMIS measures. In addition, they 
present an innovative approach in which measures are evaluated and compared across 
multiple chronic diseases and conditions. We further discuss how these findings may be used 
to support comparative effective research.
2. Background
During the first period of NIH PROMIS funding (2004–2009), several longitudinal studies 
were undertaken. Each was conducted in one of six clinical conditions: chronic heart failure 
(CHF), chronic obstructive pulmonary disease (COPD), rheumatoid arthritis (RA), cancer, 
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back pain, or major depression. These studies, the “parent studies” for this series of articles, 
addressed both substantive and psychometric research questions. For example, the back pain 
study evaluated the impact of spinal injections on individuals with back and/or leg pain and 
also investigated the responsiveness of PROMIS pain measures. The depression study 
evaluated the impact of standard treatments (medication, psychotherapy, or the combination 
of the two) in a sample of persons with clinical depression and also investigated the 
psychometric functioning of PROMIS measures of emotional distress (depression, anxiety, 
and anger). As these studies are published, their contributions will be of interest to the 
general measurement community and to researchers whose work is in one of the six clinical 
populations that were targeted.
We recognized a potential additional contribution for these studies. The data collected across 
the six clinical populations provided a unique opportunity to extend evaluation of the 
psychometric function of PROMIS measures by examining them, not within, but across 
clinical conditions. Psychometric evaluations, including the PROMIS studies described 
above, generally occur within a single clinical condition. When psychometric comparisons 
do occur, the comparisons typically are made among different measures of the same 
construct, but within a single clinical population. The tradition of conducting psychometric 
research within clinical research silos is a barrier to multiperspective evaluations that could 
be informative not only regarding the properties of measures, but also about the clinical 
character of different conditions. PROMIS is unique in that it is comprised of a team of 
investigators whose collective interests span a broad array of clinical conditions. Thus, the 
usual barrier to cross-condition investigations was removed.
With the combined data collected by the PROMIS studies, we seized the opportunity to 
conduct a set of “cross-cutting studies” that compared individual PROMIS measures across 
multiple clinical populations obtaining a multifaceted perspective on their clinical validity. 
The cross-cutting articles in this issue provide a unique perspective on the clinical validity of 
nine PROMIS measures.
3. Overview of studies
3.1. Organization and scope of studies
The cross-cutting articles in this series are organized by PRO domain rather than by clinical 
population. This is consistent with the PROMIS measurement philosophy that emphasizes 
domain-specific, rather than disease-specific measurement. Table 1 reports which domains 
and subdomains were measured and which corresponding PROMIS measures were 
administered to each of the six clinical samples. (PROMIS measures themselves are 
available in an online Appendix at www.jclinepi.com.) As evident in Table 1, a single 
domain may be represented by one or more subdomains as measured by PROMIS. In some 
of the clinical populations, all nine PROMIS domains covered in these articles were 
administered. In other samples, a subset was administered.
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3.2. Cross-study sample characteristics
The individual cross-cutting articles report sample characteristics by PROMIS domain and 
measure. Table 2 is an omnibus presentation of the demographic and clinical characteristics 
of the combined data. This information is presented by clinical condition rather than by 
PROMIS domain.
3.3. Analytic approach
As already noted, for the current series of cross-cutting articles, we combined data obtained 
from separate studies completed within specific clinical populations. These parent studies 
differed in research design, analytic approach, and research questions. We developed an 
analytic plan that fit the needs of the current set of analyses and that incorporated the 
different research designs applied in the parent studies. Some of the parent PROMIS studies, 
but not all, included an intervention. For intervention studies, changes in PROMIS scores 
over time were evaluated with particular attention to results for more proximal outcomes 
(e.g., PROMIS depression scores in the depression study). When the parent study design 
allowed, differences between known groups (e.g., COPD stable and COPD exacerbation) 
were evaluated. Although the design of several of these studies (RA, back pain, COPD, and 
major depression) included multiple follow-up assessment points, the analyses reported in 
the cross-cutting articles were restricted to results from baseline and the latest follow-up 
point.
Essential to our ability to compare measures across different clinical population was 
selection of appropriate clinical anchors. We identified candidate anchors with input from 
investigators of the parent studies. To maximize consistency across the present studies, 
consensus was reached both for global anchors (e.g., the item, “Has there been any change 
in your overall health since you started the study?” from the COPD study) and domain-
specific anchors (e.g., “How has your fatigue changed?” from the RA parent study). The set 
of anchors used across studies is reported in Table 3.
4. Summary of individual studies
4.1. Back pain
Recruitment and all procedures were approved by the University of Washington Institutional 
Review Board [13]. All participants provided informed consent.
4.1.1. Participants—A sample of 218 participants with back or leg pain was recruited 
from the University of Washington Spine Center at Harborview Medical Center (n = 131), 
Advanced Pain Medicine in Tacoma, Washington (n = 80), Virginia Mason Medical Center 
(n = 2), Roosevelt Medical Center (n = 2), Group Health Cooperative (n = 1), and from web 
site postings (n = 2). Inclusion criteria included having back and/or leg pain for at least 6 
weeks and being scheduled for spinal injection (i.e., epidural steroid injection, facet joint 
injection, or sacroiliac joint injection). Patients were excluded if they had lumbar surgery 
within the last year or had unstable neurological symptoms, cauda equine syndrome, cancer, 
spinal cord injury; vertebral fractures; or multiple sclerosis.
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Table 2 lists the demographic and clinical characteristics of the participants in this study. 
The sample’s gender composition was 56% female and primarily white, non-Hispanic 
(85%). The median age group was 55–59 years. Seventy-three percent of participants 
reported that their worst back pain during the past 7 days was 8 or above on a scale from 0 to 
10.
4.1.2. Measures—All nine PROMIS domains and subdomains were administered to the 
back pain sample at baseline and at 3 months posttreatment. Global ratings of change were 
collected using the question, “Compared to your first appointment, how would you rate your 
current back pain?” Responses of “much better” and “somewhat better” were collapsed to 
define “better”; “no change” was defined as “stable”; “somewhat worse” and “much worse” 
were collapsed to define “worse.”
4.1.3. Clinical validity questions—By collecting the scores of back pain participants 
before and after an intervention that was expected to have a favorable clinical effect, we 
were able to evaluate the responsiveness of the PROMIS measures. Because the 
interventions targeted pain, the greatest responsiveness was expected in scores from 
PROMIS measures of pain behavior and pain interference. Because all PROMIS measures 
were administered, there was opportunity to evaluate the responsiveness of PROMIS scores 
on other quality of life domains more distal to the intervention’s primary target of pain.
4.2. Cancer
Recruitment and procedures were approved by the North Shore University Health System’s 
Institutional Review Board [14]. All participants provided informed consent.
4.2.1. Participants—Participants were 310 individuals with cancer recruited from North 
Shore University Health System. The sample included outpatients with any kind of cancer 
who were beginning a new cancer treatment. Table 2 displays participants’ 
sociodemographic and clinical characteristics. The sample was predominantly female (61%) 
and white, non-Hispanic (81%). The median age group was 50–54 years.
4.2.2. Measures—PROMIS measures of physical function, fatigue, pain interference, 
depression, and anxiety were administered at enrollment in the study and at follow-up (6–12 
weeks). In addition to PROMIS measures, participants rated their levels of change with 
respect to each outcome. Five such items were presented with the stem, “Since the last time 
you filled out a questionnaire, your level of [depression, anxiety, fatigue, physical function, 
pain] is…” Responses were coded 1 (very much better), 2 (moderately better), 3 (a little 
better), 4 (about the same), 5 (a little worse), 6 (moderately worse), and 7 (very much 
worse). Responses were combined as follows: 1–3 = “better”; 4 = “about the same”; and 5–7 
= “worse.”
4.2.3. Clinical validity questions—Cancer participants completed PROMIS measures 
before or at any stage of the cancer treatment. Clinical expectations for this group were less 
clear cut than for those clinical samples in which a specific intervention was assigned and 
administered. Given the heterogeneity of where a patient may be relative to treatment, 
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patients’ score changes in the assessed domains of physical function, fatigue, pain 
interference, depression, and anxiety were expected to vary. Some participants would worsen 
due to disease progression or active treatment; some would be stable (unchanged); and 
others would improve after completing treatment. These improving and worsening patients 
would be identified by their individual global ratings of change asked at the second 
assessment. Based on prior work on the asymmetry of meaningful change, we predicted 
those patients who reported improvement in a domain would have lower effect sizes when 
compared to those who reported worsening in a domain [15,16]. Self-ratings of change 
allowed comparison of the correspondence between the magnitude of PROMIS score 
changes and participants’ self-perceived changes in outcomes.
4.3. Chronic heart failure
Institutional Review Boards at the University of Pitts-burgh and Duke University approved 
all procedures, and all participants gave informed consent.
4.3.1. Participants—Patients (N = 80) who had severe CHF and were receiving a heart 
transplant were recruited from the medical centers at the University of Pittsburgh (n = 60) 
and Duke University (n = 20). Patients were eligible based on their placement on the heart 
transplant waiting list and the attending cardiologist’s judgment that heart failure presented 
the greatest medical limitation on participant’s daily function. After exclusion of participants 
who did not receive a transplant as scheduled, a total of 60 patients are included for analysis.
The sample was primarily male (80%) and white, non-Hispanic (86%). The median age 
group was 50–54 years. Ninety-eight percent of participants were classified as having 
“marked” or “severe” limitations (New York Heart Association Functional Classifications 
III–IV) [17].
4.3.2. Measures—PROMIS measures of physical function, fatigue, depression, and 
satisfaction with participation in discretionary social activities were administered to all 
patients. Because heart transplantation often produces substantial changes in cardiac 
functioning over a relatively short period, patients were assessed at two time points: at 
baseline, when patients were put on the heart transplant registry, and at 8–12 weeks 
following the transplant procedure. In addition to PROMIS measures, participants’ 
perceptions of changes in outcomes were collected using four questions regarding the 
domains assessed with PROMIS measuresd—“How has your (depression, fatigue, ability to 
carry out your everyday physical activities, ability to carry out your usual social activities, 
and roles) changed since your heart transplant?” Responses of “got a lot better” and “got a 
little better” were collapsed to define the category “better”; “stayed the same” defined 
“same”; “got a little worse,” and “got a lot worse” were collapsed to define “worse.”
4.3.3. Clinical validity questions—The measurement of patients on PROMIS domains 
before and after heart transplant provided an opportunity to evaluate the responsiveness of 
PROMIS measures after an intervention with known clinical effectiveness. The clinical 
expectation was that, on average, participants would improve in the assessed domains of 
physical function, fatigue, depression, and anxiety. Statistically significant changes in the 
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expected direction would be evidence for the clinical validity of the targeted PROMIS 
measures. The postsurgery timing was selected as the minimum time following surgery at 
which a clinically significant improvement in functioning is typically observed.
4.4. Chronic obstructive pulmonary disease
The University of North Carolina, North Shore University Health System, University of 
Pittsburgh, and Duke University Institutional Review Boards approved the recruitment of 
participants and study procedures [18]. All participants provided informed consent.
4.4.1. Participants—A sample was recruited consisting of 185 persons with COPD. 
Participants met criteria for a clinical history of COPD according to the Global Initiative for 
Chronic Obstructive Lung Disease (Pauwels et al.) [19] definition and had at least a 10 
pack/y history of smoking. Participants were considered stable if they had been exacerbation 
free for a minimum of 2 months before enrollment. Both stable and exacerbating 
participants were enrolled. Patients were recruited through a variety of clinics and hospitals 
at participating institutions (University of North Carolina, n = 88; North Shore University 
Health System, n = 8; University of Pittsburgh, n = 47; and Duke University, n = 42). 
Participating sites recruited patients through clinic visit logs, use of a COPD registry, and/or 
patients hospitalized for an acute exacerbation of COPD. Patients were approached by a 
clinician, their designee, or research assistant (as required by site-specific regulations), who 
provided an explanation of the study and obtained informed consent.
At baseline, slightly less than half of the sample (n = 85) was classified as COPD 
exacerbation, whereas the remainder (n = 100) was classified as COPD stable. Individuals 
developing a new exacerbation during the study period were censored at the time of 
exacerbation diagnosis, resulting in 79 patients who completed the study with confirmed 
stable COPD throughout and 46 patients who were experiencing an exacerbation at baseline 
and no subsequent exacerbations during the course of the study. The demographic 
characteristics of the COPD-stable and COPD-exacerbation groups did not differ 
substantially. Forty-four percent of the COPD-stable group and 39% of the COPD-
exacerbation group were female, with both groups composed of primarily white, non-
Hispanic participants (72% and 73%, respectively). The median COPD-stable age group was 
60–64 years, and the median COPD-exacerbation age group was 55–59 years. At baseline, 
19 percent of COPD-stable participants and 43% of COPD-exacerbation reported a Medical 
Research Council breathlessness rating of grade 4, “I stop for breath after walking 100 yards 
or after a few minutes on the level” or grade 5, “I am too breathless to leave the house” [20].
4.4.2. Measures—PROMIS measures of physical function, pain interference, pain 
behavior, depression, anxiety, anger, fatigue, satisfaction with participation in discretionary 
social activities, and satisfaction with participation in social roles were administered. 
Participants completed assessments at baseline, followed by weekly short assessments, and a 
3-month comprehensive follow-up assessment that included a global assessment of change 
at follow-up. For the clinical validity questions addressed in this series of cross-cutting 
articles, the final 3-month assessment was compared to baseline.
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Participants reported changes in general health by responding to the question, “Has there 
been any change in your overall health since you started the study?” using the following 
response options: 1 (“very much worse”), 2 (“moderately worse”), 3 (“a little worse”), 4 
(“about the same”), 5 (“a little better”), 6 (“moderately better”), or 7 (“very much better”). 
At each time point, participants responded to global questions about the domains assessed 
by PROMIS measures. Scores on these items at baseline were subtracted from scores at 
follow-up to operationalize classification as worse, same, or better. The item used for 
defining changes in depression and anxiety was “How often have you been bothered by 
emotional problems such as feeling anxious, depressed or irritable?” To define changes in 
fatigue the item, “How would you rate your fatigue on average?” was administered. For 
physical function, the item administered was “To what extent are you able to carry out your 
everyday physical activities such as walking, climbing stairs, carrying groceries, or moving a 
chair?” For social function, the item was “In general, please rate how well you carry out 
your usual social activities and roles [etc.]” For pain interference and pain behavior, the item 
was “How would you rate your pain on average?” For depression, anxiety, pain, and fatigue, 
individuals who had higher follow-up scores than baselines scores were classified as 
“worse,” lower follow-up scores defined “better,” and equal values at baseline and followup 
defined “same.”
4.4.3. Clinical validity questions—The purpose of examining the PROMIS measures in 
this clinical setting was to evaluate the success of scores in discriminating persons with and 
without COPD exacerbation. The clinical expectation was that, on average, participants who 
had an exacerbation would have worse scores than persons without an exacerbation [21,22]. 
Because both stable and participants with an exacerbation were evaluated at two time points, 
the sensitivity of PROMIS measures over time was evaluated. The expectation was that 
those with an exacerbation at enrollment would improve in outcomes over the 3-month 
period, but there were no such expectations for those who began and completed the study 
classified as stable.
4.5. Rheumatoid arthritis
The Stanford University Institutional Review Board approved the study and informed 
consent was obtained for all participants [23,24].
4.5.1. Participants—PROMIS measures of physical function, fatigue, and pain 
interference were administered to 521 individuals with RA at baseline, 6 months, and 12 
months. Measures evaluated longitudinal changes in a clinical population receiving routine 
care. All participants met the American College of Rheumatism criteria for RA. Our sample 
of patients was drawn from two sources: (1) the Aging Medical Information System and (2) 
the Stanford RA Registry, which provided patients who are enrolled in generic studies. Table 
2 reports the demographics of the sample. Briefly, most were female (81%) and white, non-
Hispanic (88%). The median age group was 65–69 years. Participants were seeing their 
rheumatologist for care and may or may not have been receiving a clinical intervention.
4.5.2. Measures—PROMIS measures of pain, physical function, and fatigue were 
administered to the RA sample at baseline and at a final follow-up of 12 months. In addition, 
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participants provided global ratings of change in outcomes by answering the questions: (1) 
How has your fatigue changed? (2) How has your ability to carry out your everyday physical 
activities such as walking, climbing stairs, carrying groceries, or moving a chair changed? 
And (3) How has your pain changed? Responses were 1–5. For all three domains, responses 
of 1 (“got a lot better”) and 2 (“got a little better”) were considered “better;” 3 (“stayed the 
same”) considered “the same;” and 4 (“got a little worse”) and 5 (“got a lot worse”) 
considered “worse.”
4.5.3. Clinical validity questions—The purpose of examining the PROMIS measures in 
this clinical setting was to evaluate the longitudinal trajectory in outcomes of persons with 
RA. Clinical expectations for this group were less clear cut than for those clinical samples in 
which a known intervention was assigned and administered. Although participants were 
receiving regular care that could include intervention, they also were experiencing a disease 
that is known to worsen over time. The inclusion of this sample allowed us to evaluate 
PROMIS measures in a heterogeneous chronic condition sample whose outcomes were 
thought to be more reflective of real-world RA populations not enrolled in clinical research 
trials. Self-ratings of change allowed comparison of the correspondence between the 
magnitude of score changes and participants’ self-perceived changes in outcomes.
4.6. Major depressive disorder
The University of Pittsburgh’s Institutional Review Board approved the study, and all 
participants provided informed consent [25].
4.6.1. Participants—A sample of 196 participants was recruited from outpatient treatment 
clinics at Western Psychiatric Institute and Clinic (WPIC, n = 136), Dubois Regional 
Medical Center Behavioral Health Services (n = 29), and private practitioners located in the 
Pittsburgh metropolitan area (n = 31). Participant recruitment procedures involved the 
distribution of IRB-approved study promotional materials at WPIC and its affiliates. The 
promotional materials encouraged potential participants to call or to visit the research staff, 
at which time an initial screening took place. Participants were excluded if they were 
undergoing current psychiatric inpatient treatment or had a lifetime history of any psychotic 
disorder (e.g., schizophrenia, schizoaffective disorder) or bipolar disorder documented in 
medical records or reported during the Structured Clinical Interview for DSM-IV [26]. Most 
patients received a combined treatment of medication and psychotherapy (64%), whereas 
smaller proportions received medication only (28%) or psychotherapy only (8%). 
Participants completed PRO measures at baseline and after 3 months.
Participant sociodemographic and clinical characteristics are described in Table 1. Most of 
the patients were female (74%) and white, non-Hispanic (78%). The median age group was 
45–49 years. Forty-four percent of participants reported a Center for Epidemiologic Studies 
Depression Scale [27] score of 28 or above.
4.6.2. Measures—The following PROMIS measures were administered at baseline and at 
3-month follow-up: physical function, fatigue, pain behavior, pain interference, depression, 
anxiety, anger, satisfaction with participation in social roles, and satisfaction with 
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participation in discretionary social activities. In addition, participants rated their change 
with respect to depression by answering the question, “Compared to your first appointment, 
how would you rate your current level of depression?” Responses ranged from −2 to +2. 
Responses of −2 and as −1 were coded as “worse,” 0, “same” and 1 and 2 as “better.” In 
addition, participants rated their general health by responding to the item, “Is your health 
excellent, very good, good, fair, or poor?” Positive and negative increments were coded as 
“better” and “worse,” respectively. No change was coded as “same.”
4.6.3. Clinical validity questions—The purpose of administering PROMIS measures in 
major depressive disorder (MDD) was to evaluate the responsiveness of PROMIS measures 
to MDD treatment. The clinical expectation was that participants’ scores would improve 
most on the most proximal subdomains of depression and anxiety.
5. Analyses
As reported above, different clinical samples lent themselves to different research questions, 
but all analyses contributed to understanding the clinical validity of the PROMIS domain 
measures. Another point of analytic continuity was the use of global and clinical anchors 
(such as perceived improvement in health) that were consistent within clinical groups and 
comparative across populations. Table 3 identifies the selected global and clinical anchors by 
clinical sample.
For each PROMIS instrument and each clinically anchored subgroup, the authors of each 
article report the change in T-scores and the standardized response mean (SRM). The SRM 
is the ratio of the mean change to the standard deviation of that change [28], which is a form 
of Cohen’s effect size index [29]. A minimally important difference in PRO measures was 
operationalized as an effect size of 0.30 [30,31]. PROMIS instruments use the convention of 
higher scores indicating more of the domain for which the measure is named.
Some studies (e.g., depression, back pain) included an intervention. For these studies, 
changes in PROMIS scores over time were evaluated with particular attention to results for 
more proximal outcomes (e.g., PROMIS pain scores in the back pain study, PROMIS 
depression scores in the depression study).
When appropriate, differences between known groups (e.g., COPD stable and COPD 
exacerbation) were evaluated. This was accomplished using linear mixed models estimated 
with random subject effects to account for the correlation among repeated observations 
within individuals [32,33]. A mixed model is advantageous because all available data can be 
used, including that from participants who did not provide data at both time points [34,35]. 
Least squares means, standard errors, and 95% confidence intervals were estimated from the 
models.
At baseline, completion rates for the individual PROMIS measures ranged from 95% to 
100%, whereas 79–95% of study participants completed the measures at follow-up. We 
compared baseline characteristics of participants with complete data to those with 
incomplete data, pooling across conditions. There were some differences, indicating that 
missing data were not missing completely at random (MCAR). It is not possible to test for 
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the appropriateness of the missing at random (MAR) assumption compared to missing not at 
random. We judged the MAR assumption, conditional on the observed data (i.e., baseline 
scores), to be reasonable in this setting. The mixed effects models implemented in the 
analyses assume MAR (conditional on observed data in the model) and incorporate all 
available data. All analyses appropriate for MAR data are also appropriate for MCAR data. 
An alternative MAR strategy is multiple imputations; however, because baseline scores are 
historically the strongest predictor of follow-up scores, multiple imputations with additional 
variables in the model was not expected to improve substantially on the mixed model 
analyses.
6. Summary
This series of articles provides practical information on the responsiveness of several 
PROMIS domains across six clinical validation studies. Cumulatively, they report clinical 
validity findings for nine PROMIS measures, representing five PROMIS domains, evaluated 
across six clinical conditions, and including approximately 1,500 individuals at baseline and 
1,300 at follow-up. The cross-condition focus of the analyses provides a unique and 
multifaceted perspective on how PROMIS measures function in “real-world” clinical 
settings. The results support the use of PROMIS measures across several chronic conditions.
Perhaps, the most practically useful research products in this series of studies are the graphs 
that show differences in PROMIS scores across time and across clinical condition and 
clinical subgroups. The graphs not only demonstrate the psychometric properties of the 
PROMIS measure being evaluated, but they express differences in clinical characteristics of 
the included chronic conditions. The graphs are succinct presentations of the validity of 
using scores from a given PROMIS measure for specific clinical questions.
Because the validity results for each PROMIS domain were based on multiple clinical 
samples, no single study can collect all the relevant clinical validity evidence for a given 
measure. The same observation can be made about any single series of studies. However, the 
cross-cutting studies reported in this issue provide substantial support for the clinical validity 
of nine PROMIS measures in a range of chronic conditions. We think the results have 
implications for the practical application of PROMIS tools. In addition, we think the analytic 
strategy is informative, practical, and innovative. We are hopeful that this unique, across-
condition analytic approach will be repeated in future psychometric studies using both 
retrospective and prospective data.
6.1. Limitations
The analyses reported in this issue were conducted post hoc, pooling data across six distinct 
studies. We developed an analytic plan that accommodated the different designs of the six, 
within-condition, parent studies and maximized our ability to make relevant comparisons 
across conditions. A stronger approach would have been to develop, a priori, a data 
collection method, research design, and analytic approach that focused specifically on the 
purpose of the current set of studies—the cross-condition, psychometric evaluation of the 
PROMIS measures.
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We used retrospective reports of change and differences in global scores from baseline to 
follow-up. Limiting the analyses to these anchors is a limitation of the studies. (A related 
issue is the fact that multiple cut-points could have been chosen to trichotomize change into 
“worse,” “same,” and “better.”) Anchoring estimates of change based on global self-reports 
have intuitive appeal, but it also has limits. Retrospective, self-reported global change ratings 
have been shown to be vulnerable to response bias [36]; and they may be more related to 
current status than to change [5,37]. An ideal design would include estimates based on 
multiple anchors. For some conditions, external anchors such as clinician ratings, functional 
capacity tests, and work status could be incorporated. Provision of a range of estimates 
based on multiple anchors recognizes that there is no gold standard anchor, nor “true” 
estimate of meaningful change, a fact obscured when researchers report a measure’s 
“minimally important difference” or “clinically meaningful difference” as a single score 
value. A more sound approach is to triangulate estimates of meaningful score changes to 
estimate a defensible range of estimates [38]. Although it is not possible to capture “the 
truth,” there are ways to “get it surrounded.” Toward this end, we recommend future studies 
that include a larger range of clinical anchors and contexts.
There is a few additional limitations of these studies. Although PROMIS was developed 
including numerous people across a variety of races and ethnicity, the participants in these 
studies are predominately non-Hispanic whites. In addition, many of the authors were 
PROMIS investigators who participated in the development of the measures being evaluated. 
The PROMIS process was extended and challenging, and it is likely that the investigators 
involve retain some “pride of ownership” that could influence their presentations and 
interpretations of results. This is an issue in any validity study conducted by a measure’s 
developers. The authors recognize this potential influence, acknowledge it, and have 
attempted to minimize it.
6.2. Implications for CER
Despite the limitations in the studies in this issue, the results have significant potential for 
supporting CER. The observed score changes and score differences among clinical 
subpopulations could serve as defensible estimates of what constitutes clinically meaningful 
change and, by extension, provide empirical support for responder definitions. Again, we 
emphasize that there is no single, definitive score change that constitutes a meaningful or 
important change for all settings or for all purposes. But a strength of this study is its 
evaluation of the measures in a wide range of clinical populations, providing several 
perspectives for defining meaningful changes in scores and responders to interventions. For 
example, Schalet et al. (Schalet et al., 2014; submitted data) (this volume) report changes in 
PROMIS anxiety scores in four clinical populations including COPD. The mean PROMIS 
anxiety scores for individuals experiencing a COPD exacerbation was 60.2. After resolution, 
the mean dropped to 55.9—a difference of 4.3 points. This data point could be very 
informative for use in a clinical trial of a self-management intervention in COPD that is 
expected to reduce anxiety in participants. When used along with other available anchors 
and supported by distributional estimates, the information helps justify a responder 
definition.
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In summary, the findings presented in cross-cutting studies in this issue provide unique and 
multifaceted perspectives on how PROMIS measures function in a range of clinical 
populations. The results support CER and add to the growing body of validity evidence for 
PROMIS measures used in a range of chronic conditions. Future studies can help define the 
strengths and limitations of the PROMIS measures by including additional clinical 
populations and a wider range of clinical anchors.
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Refer to Web version on PubMed Central for supplementary material.
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What is new?
Key findings
• There is substantial clinical validity evidence that National Institutes of 
Health’s Patient Reported Outcome Measurement Information System 
was successful in developing measures that are effective across a range 
of chronic conditions.
What this adds to what was known?
• The results add to what is known about the properties of the targeted 
PROMIS measures.
• The weight of evidence supports the appropriateness of using PROMIS 
measures across varied clinical populations.
What is the implication and what should change now?
• Findings support the fitness of PROMIS measures in clinical and 
comparative effectiveness research.
• Results should be considered when establishing responder criteria for 
comparative effectiveness research.
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ra
te
 y
ou
r a
v
er
ag
e 
pa
in
? 
[0
 to
 10
]
H
ow
 h
as
 y
ou
r p
ai
n 
ch
an
ge
d?
 
[g
ot 
a l
ot 
be
tte
r, g
ot
 a
 li
ttl
e 
be
tte
r, 
st
ay
ed
 th
e 
sa
m
e,
 g
ot
 a
 
lit
tle
 w
o
rs
e,
 g
ot
 a
 lo
t w
o
rs
e]
 
So
ci
al
H
ow
 h
as
 y
ou
r a
bi
lit
y 
to
 
ca
rr
y 
ou
t y
ou
r u
su
al
 
so
ci
al
 a
ct
iv
iti
es
 a
nd
 
ro
le
s c
ha
ng
ed
 si
nc
e 
yo
ur
 h
ea
rt 
tra
ns
pl
an
t?
 
[g
ot 
a l
ot 
be
tte
r, g
ot
 a
 
lit
tle
 b
et
te
r, 
st
ay
ed
 th
e 
sa
m
e,
 g
ot
 a
 li
ttl
e 
w
o
rs
e,
 
go
t a
 lo
t w
o
rs
e]
In
 g
en
er
al
, h
ow
 w
o
u
ld
 y
ou
 
ra
te
 y
ou
r s
at
isf
ac
tio
n 
w
ith
 
yo
ur
 so
ci
al
 a
ct
iv
iti
es
 a
nd
 
re
la
tio
ns
hi
ps
? 
[ex
ce
lle
nt
, 
v
er
y 
go
od
, g
oo
d,
 fa
ir,
 
po
or
]
A
bb
re
v
ia
tio
ns
: C
H
F,
 
ch
ro
ni
c 
he
ar
t f
ai
lu
re
; C
O
PD
, c
hr
on
ic
 o
bs
tru
ct
iv
e 
pu
lm
on
ar
y 
di
se
as
e.
Fo
r 
co
n
sis
te
nc
y 
of
 p
re
se
nt
at
io
n,
 th
e 
or
de
r o
f r
es
po
ns
e 
ca
te
go
ry
 o
pt
io
ns
 a
re
 re
v
er
se
d 
fro
m
 th
e 
di
re
ct
io
n 
th
ey
 w
er
e 
pr
es
en
te
d 
to
 p
at
ie
nt
s.
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